New drug HLX43 targets tough esophageal cancers
NCT ID NCT06769113
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a drug called HLX43 in 102 people with advanced esophageal cancer that did not respond to or could not tolerate standard first-line therapy. HLX43 is an antibody-drug conjugate designed to deliver a chemotherapy agent directly to cancer cells. The study aims to see if the drug can shrink tumors and how safe it is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HLX43 (an antibody-drug conjugate that targets PD-L1 and delivers a chemotherapy drug directly to cancer cells)
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced esophageal cancer who have run out of standard therapies.
- What could go wrong
- This is a mid-stage trial with only 102 participants, so results may not apply to everyone. The drug may cause side effects or not shrink tumors as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Cancer Hospital
RECRUITINGJinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can 3D motion capture reveal hidden breathing problems after esophageal cancer surgery?
- Can Real-World data improve esophageal cancer care in africa?
- Stent showdown: which esophageal prosthesis best restores swallowing in advanced cancer?
- DNA clues may reveal which esophageal cancers will return soon after surgery
- Can a condensed radiation blast plus chemo keep esophageal cancer at bay?